Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy

Tumori

Volumn 100, Issue 3, 2014, Pages 328-332

  Zhang, Zhongxin ^a,b   Jiang, Changqing ^b   Hu, Likuan ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Concurrent chemoradiotherapy; Excision repair cross complementation group 1 (ERCC1); Locally advanced; Nasopharyngeal cancer

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT RESPONSE; COMPARATIVE STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DNA-BINDING PROTEINS; DOWN-REGULATION; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84921632028     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1578.17218     Document Type: Article

References (35)

1. Sun JM, Ahn MJ, Park MJ, Lee HY, Ahn JS, Lee S, Kang G, Han J, Son YI, Baek CH, Ahn YC, Park K: Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys, 80: 655-660, 2011.
2. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol, 16: 1310-1317, 1998. (Pubitemid 28175745)
3. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol, 21: 631-637, 2003.
4. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HS, Lee KS, Loong S, Sethi V, Chua EJ, Machin D: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol, 23: 6730-6738, 2005. (Pubitemid 46190268)
5. Qin DX1, Hu YH, Yan JH, Xu GZ, Cai WM, Wu XL, Cao DX, Gu XZ: Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer, 61: 1117-1124, 1998.
6. Zhang EP1, Lian PG, Cai KL, Chen YF, Cai MD, Zheng XF, Guang XX: Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1302 patients. Int J Radiat Oncol Biol Phys, 16: 301-305, 1989.
7. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC: Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst, 97: 536-539, 2005. (Pubitemid 40590436)
8. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators: DNA repair by ERCC1 in non-small- cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355: 983-991, 2006. (Pubitemid 44343542)
9. Darcy KM, Tian C, Reed E: A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res, 67: 4474-4481, 2007. (Pubitemid 46815098)
10. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 18: 504-509, 2007. (Pubitemid 46359630)
11. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91: 344-354, 2004. (Pubitemid 39037082)
12. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB: ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer, 44: 54-60, 2008. (Pubitemid 350256935)
13. Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC, Zhang L: Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cis-platin- based induction chemotherapy. Oral Oncol, 48: 964-968, 2012.
14. Sun JM, Sung JY, Park SH, Kwon GY, Jeong BC, Seo SI, Jeon SS, Lee HM, Jo J, Choi HY, Lim HY: ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer, 12: 187, 2012.
15. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E: Excision repair cross complementation group 1 immuno-histochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res, 13: 3855-3859, 2007. (Pubitemid 47037591)
16. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 17: 1818-1825, 2006. (Pubitemid 44884058)
17. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res, 63: 1311-1316, 2003. (Pubitemid 36348710)
18. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8: 2286-2291, 2002. (Pubitemid 34753602)
19. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D: ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer, 89: 453-457, 2000.
20. Larminat F, Bohr VA: Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res, 22: 3005-3010, 1994. (Pubitemid 24260628)
21. Guo WF, Lin RX, Huang J, Zhou Z, Yang J, Guo GZ, Wang SQ: Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res, 164: 27-35, 2005. (Pubitemid 40885227)
22. Jeong J, Hong SJ, Ju YJ, Kim BY, Park MJ, Kim TH, Park CI, Choi KY, Cho MH, Kim SH, Lee H, Lee KH: Temporal cDNA microarray analysis of gene expression in human hepatocellular carcinoma upon radiation exposure. Oncol Rep, 15: 33-48, 2006.
23. Murray D, Rosenberg E: The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res, 364: 217-226, 1996. (Pubitemid 26408461)
24. Doll CM, Craighead P, Diaz R, Box A, Shin B, Eliasziw M, Lees-Miller S, Magliocco AM: High ERCC1 expression is associated with worse survival in patients with locally advanced cervical cancer treated with radiotherapy (RT): an evaluation of AQUA® versus conventional IHC methods. Int J Radiat Oncol Biol Phys, 72: S18-S19, 2008.
25. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB: ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer, 44: 54-60, 2008. (Pubitemid 350256935)
26. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV, Harpole DH Jr: High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res, 11: 2215-2221, 2005.
27. Nix P, Greenman J, Stafford N, Cawkwell L: Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Ther, 2: 47-53, 2004.
28. Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M, Kuwano M, Aizawa H: Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol, 64: 565- 573, 2009.
29. Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K: ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer, 113: 1379-1386, 2008.
30. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K: ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer, 99: 167-172, 2008. (Pubitemid 351920246)
31. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ: The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a metaanalysis of the published literature. J Clin Oncol, 22: 4604- 4612, 2004.
32. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP; MAC-NPC Collaborative Group: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys, 64: 47-56, 2006. (Pubitemid 41831208)
33. Chua DT, Nicholls JM, Sham JS, Au GK: Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys, 59: 11-20, 2004. (Pubitemid 38501502)
34. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 59: 1188-1191, 1999. (Pubitemid 29136244)
35. Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ: Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res, 60: 6878-6881, 2000. (Pubitemid 32059157)